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Glaucoma is a term describing a group of ocular disorders with multi–factorial 
aetiology united by a clinically characteristic, intraocular pressure–associated optic 
neuropathy.
1
 Pathologically, there is a loss of retinal ganglion cells (RGCs), including 
their axons, which comprise the retinal nerve fibre layer (RNFL) and optic nerve. The 
most common subtype is primary open–angle glaucoma (POAG). Intraocular pressure 
(IOP) reduction is currently the only treatment strategy for POAG, and although this 
retards the average rate of neurodegeneration,
2
 some maximally–treated patients 
continue to progress, and it remains the world’s leading cause of irreversible 
blindness.  
The pathogenesis of POAG remains unclear, but impaired ocular perfusion pressure is 
a well–documented risk factor,3, 4 a fact that is consistent with the “vascular theory of 
glaucoma” and suggesting that energy insufficiency at the optic nerve head and retina 
is part of the pathogenesis in at least a proportion of individuals with POAG. 
We have previously shown that elevated vitreous glucose levels provide robust 
neuroprotection against an experimental model of acute retinal ischaemia.
5
 This 
finding was consistent with earlier experiments demonstrating a decline in vitreous 
glucose concentration during periods of retinal ischaemia in rabbits,
6
 suggesting that 
the energy–deprived retina metabolizes glycolytic substrates in the vitreous reservoir, 
a phenomenon that could potentially be clinically exploited.  
We subsequently showed the neuroprotective effect of glucose against prolonged 
ischaemic retinal injury,
5, 7
 and more recently extended the protective effect to a 
rodent model of glaucomatous optic nerve neurodegeneration.
8
 In vitro evidence from 




glycolytic adenosine triphosphate (ATP) production and anti–oxidant generation via 
glucose entry into the pentose phosphate pathway (unpublished data). 
In the experimental models and clinical POAG, we conceptualize RGCs as existing in 
a tripartite population, comprising healthy, “sick” and dead cells.9 Conceivably, 
delivery of an energy substrate combined with cellular reducing power to “sick” 
RGCs may serve to recover function, providing a form of temporary neurorecovery.
9
 
In the current study, we aimed to demonstrate recovery of a relevant visual 
psychophysical parameter, contrast sensitivity, as a clinical substrate of neurorecovery 
in patients with POAG. This study represents a “first to man” attempt to translate our 
retinal bioenergetics research from the laboratory to the clinic.  
 
Methods 
Phase 1 glucose delivery study  
Preliminary testing on health volunteers (RJC and AE) indicated that topical 50% 
glucose was well tolerated and had no discernible effect on the cornea or IOP. The 
aim of the Phase I study was to determine whether 50% topical glucose delivery could 
reach the vitreous chamber without adverse effects in either phakic or pseudophakic 
patients. The study was registered online with the Australian and New Zealand 
Clinical Trial Registry (ANZCTR; ACTRN12611001225909) The study was 
designed as a dose escalation trial on non–diabetic patients scheduled for epiretinal 
membrane peel or macular hole repair by experienced vitreoretinal surgeons (JG and 
HSN). In the immediate pre–operative period, subjects received 5–minutely drops for 
60 minutes. A vitreous sample was taken at the start of surgery (15–30 minutes after 
the last drop) and immediately sent for analysis of glucose concentration. Initial 




glucose concentration of 3·0 mmol (SD 0·28). Allowing for greater variance in a 
treated group, we estimated that a sample size of 4 treated subjects would provide 
over 90% power to detect a 25% increase in glucose concentration with an alpha 
value of 0·05. In addition to this sample, the dose escalation protocol required that the 
glucose concentration was increased from 10% to 25% to 50%, with two patients 
receiving a given dose and neither permitted to have any adverse effects before 
proceeding to the next concentration. Having noted no adverse effects at any 
concentration, we treated 4 phakic patients and 4 pseudophakic patients with 50% 
topical glucose. The data were analysed using a regression analysis with glucose 
concentration as the response variable and group as the predictor. Compared to the 
control subjects, the vitreous glucose concentration was significantly elevated in 
pseudophakic (p = 0·02) but not phakic patients (Fig. 1). 
The effect of topical glucose on visual function (Study 1) 
This study was a double–blind, randomized crossover, first–in–man, trial to determine 
the effect of topical glucose on psychophysical biomarkers in patients with POAG.   
Inclusion/exclusion criteria 
Non–diabetic pseudophakic patients with definite POAG were recruited from RJC’s 
clinics.  Other ocular pathology was an exclusion criterion, but previous glaucoma 
filtering surgery (at least 12 months prior) or glaucoma medications were permitted. 
Eyes were required to have at least six 24–2 Humphrey Field Analyzer (Humphrey 
Instruments, Dublin, CA, USA) field tests with consistent or progressing 
glaucomatous field defects and a cup to disc ratio of at least 0·8. All eyes had 
undergone phacoemulsification with “in the bag” intraocular lens (IOL) placement at 
least 12 months prior to commencement of the study. If both eyes in one individual 




Randomization and masking 
The study was registered online with ANZCTR (ACTRN12612001134819) and was 
conducted in the Ophthalmology Department of the Royal Adelaide Hospital. The 
trial profile is shown in Figure 2. Using a computer–generated random sequence 
contained in sealed envelopes, eyes were allocated to receive either 50% glucose then 
0’9% saline or vice versa with a “washout period” of 2–3 weeks. Sterile drops were 
formulated and dispensed by the hospital pharmacy in coded but identical bottles. 
Neither the researchers collecting the data nor the patients knew the contents of each 
bottle.  The drops were administered 5 minutely for 1 hour, as per the protocol in the 
Phase I study. We elected to use 0·9% saline because we felt that highly concentrated 
saline would not be well tolerated by patients; however, we were aware that the 
osmolarity was not matched to the glucose (see Study 2 below).  
Data collection 
Prior to instillation of the drops we recorded the following baseline measurements: 
the best–corrected logarithm of the minimum angle of resolution (logMAR) acuity of 
each eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart; 
contrast sensitivity using the CSV–1000 (VectorVision, Ohio,U.S.A.); refraction; 
IOP; central corneal thickness (CCT); blood glucose; and blood pressure. Age, gender 
and the average of the most recent 3 mean deviations (MD) from the field test data 
were also recorded.  
The CSV–1000 measures contrast sensitivity at 4 spatial frequencies: 3, 6 12, and 18 
cylcles per degree. If the logMAR is > 0·6 (approximately 6/24 Snellen acuity), then 
contrast sensitivity testing with this method is considered inaccurate and was 
therefore not performed, as per the manufacturers recommendations (VectorVision, 




recorded in log units as per the manufacturer’s recommendations (VectorVision, 
Ohio, U.S.A.).  For eyes with an unrecordable acuity on the ETDRS chart, we 
assigned a logMAR value 0f 2·00 for “count fingers” and 2·30 for “hand 
movements”. 10 
All measurements were recorded again 15–30 minutes after the instillation of the last 
drop.  
 Outcomes 
The primary outcome was the change in contrast sensitivity at 12 cycles/degree. 
Secondary outcomes were change in contrast sensitivity at 3, 6, and 18 cycles/ degree 
and change in the logMAR acuity. 
Ethics 
The study was conducted in accordance with the Declaration of Helsinki, and was 
approved by the Human Research Ethics committee at the Royal Adelaide Hospital. 
All patients gave written informed consent to participate. 
Statistical analysis 
Exploratory data analyses were performed and a generalized estimating equation 
(GEE) approach was used for parameter estimation to account for the correlated 
nature of the data. To overcome the non–normality of the response variables in a data 
set with a relatively small cluster size, bootstrapping with 1000 replications was used 
to estimate the variance of the regression parameters, and a Wald test was used for 
hypothesis testing. A p value < 0·05 was considered statistically significant; 
commercially available statistical software was used for the analyses (Stata Statistical 
Software: Release 12. College Station, TX: StataCorp LP) 
Role of the funding source 




collection, analysis or interpretation. The corresponding author and his coauthors had 
full access to all the data in the study, made a final data interpretation that was 
unbiased by the sponsor, and made the final decision to submit for publication. 
 
Results of Study 1 
Baseline data 
The mean age of the participants was 77·2 years (SD 7·7) Eyes generally had 
moderate to severe glaucoma with an average MD of –12·1  (SD 9·8). The mean 
baseline logMAR was .22 (SD ·33), and the mean baseline contrast sensitivity at 12 
cycles/degree was 0·91 (SD ·51) log units. 
Effect on contrast sensitivity and acuity 
The exploratory data analysis indicated that glucose tended to increase both the log 
contrast sensitivity at 12 cycles/degree and the logMAR acuity (boxplots of the 
dataset are shown Fig. 3 and Fig. 4). The GEE regression analysis confirmed that 
saline caused no change (0·003 log units) from baseline in the contrast sensitivity at 
12 cycles/degree. However, glucose significantly increased contrast sensitivity at 12 
cycles/degree by 0·26 (95% CI: 0·13 – 0·38) log units (p < 0.001; Fig. 5). Saline had 
a similarly negligible effect at the other spatial frequencies; however, glucose 
improved the mean contrast sensitivity at 3, 6, and 18 cycles/degree by 0·20 (95% CI: 
0·14 – 0·25), 0·17 (95% CI: 0·07 – 0.27), 0.14 (95% CI: –0·01 – 0·28), respectively 
(Fig. 6). 
Saline had no effect on acuity; however, in the regression model, glucose increased 
the mean logMAR acuity by 0·04 (95% CI: –0·07 – .005; p = 0·025) 
The effect on IOP, CCT and refraction 




503·1 μm (SD 70·6). The mean baseline spherical equivalent was –0·93 dioptres  (SD 
1·81). There was no significant change in any of these parameters after saline or 
glucose.  
The effect of topical glucose on visual function (Study 2) 
The Study 1 results suggested a positive effect of glucose on psychophysical 
biomarkers in patients with POAG. However, the fact that the saline osmolarity was 
not matched to the glucose raised concerns about the possibility of an optical effect on 
the cornea. Although we were concerned about a hyperosmolar solution having a 
detrimental effect on the corneal epithelium, conceivably a hyperosmolar agent may 
cause relative dehydration of the corneal stroma, potentially leading to improved 
visual function. To test the  hypothesis that the result from study 1 was optically–
induced, we invited back participants from study 1 who had responded positively. 
Based on the treatment effect and variance observed in Study 1, we estimated that a 
sample size of 9 eyes would provide an 80% power at an alpha value of 0.05 to detect 
a treatment effect on contrast sensitivity at 12 cycles/degree of the same magnitude as 
Study 1. We recruited 4 patients from the original study and a further 3 suitable 
patients (a total of 14 eligible eyes). 
The protocol for this repeat study was identical to Study 1 except that patients 
received 8% saline (osmolarity matched to 50% glucose). 
Results of Study 2    
Baseline data 
The study flow chart is shown in Figure 6. The mean age of the participants was 74·5 
years (SD 6·3). The mean baseline logMAR was 0·57 (SD ·92), and the mean 
baseline contrast sensitivity at 12 cycles/degree was 0·33 (SD 1·2). 




Exploratory data analyses again indicated that glucose tended to improve both the 
contrast sensitivity at 12 cycles/degree and the visual acuity (boxplots of the dataset 
are shown in Figs. 7 and 8). In the GEE analysis, saline caused a small but non–
significant mean reduction in contrast sensitivity at 12 cycles/degree (0·10 log units, 
95% CI: –0·26 – 0·06). Glucose significantly improved the contrast sensitivity at 12 
cycles/degree by 0.86 log units (95% CI: 0·17 – 1.5; p = 0·014). Saline had a small 
non–significant negative effect at the other spatial frequencies.  Glucose significantly 
improved the mean contrast sensitivity a 6 cycles/degree by 0·28 (95% CI: 0·12 – 
0·44) log units, but had no significant effect at 3 or 18 cycles/degree, 0.07 (95% CI:–
0·09 – 0·23) log units and 0·08 (95% CI: –0·09 – 0·26) log units, respectively (Fig. 
9). 
The effect on IOP, CCT and refraction 
The mean baseline IOP was 10·9 mmHg (SD 3·5). The mean baseline CCT was 
505·3 μm (SD 36·1). The mean baseline spherical equivalent was –0·93 dioptres   




This study provides one of the first attempts to translate a novel treatment strategy to 
glaucoma patients using an efficient methodological paradigm, albeit a “lower 
hanging fruit” than demonstrative neuroprotection. 
Neuroprotection is the relative preservation of neurons.
9
 It indicates a reduction in the 
rate of loss of neurons, and by definition is a mathematical function of time. For 
chronic neurodegenerative diseases like POAG, neuroprotection takes months to 
years to convincingly demonstrate.
9




translation of neuroprotective research. In contrast, neurorecovery is the complete or 
partial restoration of a “sick” neuron to structural and/or functional health.9 It is 
distinguished by the fact that it can be demonstrated over a short time period.
9
 For 
example, we conceptualize the recovery of vision due to restoration of the retinal 
circulation following an episode of “grey–out” experienced by pilots during 
acceleration stress as an example of neurorecovery. Similarly, in 1941, McFarland 
and Forbes demonstrated glucose–induced recovery of dark adaptation in hypoxic 
human subjects, which occurred over short time intervals.
11
  
Rather than aiming to demonstrate a neuroprotective effect, we elected to demonstrate 
temporary glucose–induced recovery of visual psycophysical parameters in patients 
with POAG.  Although the notion of sick RGCs in glaucoma is widely discussed, 
direct evidence for their existence largely comes from experimental models.
12
 
However, human studies have shown that IOP reduction can recover RGC function, 
as demonstrated electrophysiologically,
13




Contrast sensitivity refers to the ability to discern between different light (luminance) 
levels. It is an important aspect of human vision, and is impaired
16, 17
 in POAG. 
Reduction in contrast sensitivity is well correlated with vision–related quality of life 
in POAG.
18
 Furthermore, contrast sensitivity was shown to rapidly but temporarily 
recover after calcium channel blockade in patients with normal tension glaucoma.
19
 
The convergence of evidence indicates that contrast sensitivity in glaucoma is most 
affected at a spatial frequency of 12 cycles/degree Hence, we chose this as our study 
primary outcome.{Sample, 1991 #370;Gandolfi, 2005 #207} 
In experimental animals, the steady–state vitreous glucose concentration is 




causes a corresponding increase in vitreous glucose, which shows a slower rate of 
decline than blood as normoglycaemia is restored.
20
 Although human data describing 
the relationship between plasma glucose and vitreous glucose concentration is scarce, 
vitreous glucose is routinely used in forensic medicine as a marker of blood glucose at 
the time of death.
21
  To our knowledge, there is only one previous report on the blood 
and glucose concentrations in living human subjects.
22
 Our own findings from the 
non–diabetic patients in the initial phase of the study were consistent with this report.  
An initial consideration in this study was the delivery method of glucose to the eye. 
We elected to use topical glucose delivery. Arguably, this is not an efficient method 
of drug delivery to the vitreous chamber; however, our rationale was that glucose is a 
small molecule and it was biologically plausible that it would penetrate the ocular 
coats. Furthermore, we felt the risk/benefit ratio of alternative delivery methods such 
as intravitreal injection were not acceptable. Theoretically, the vitreous glucose 
concentration could have been elevated by rendering the subjects hyperglycaemic; 
however, the physiological effects of hyperglycaemia include IOP reduction; hence, 
this would have been a problematic confounder.  Given that the permeability of 
hydrophilic glucose was likely to be poor, we aimed to deliver a high concentration 
and volume to the eye to optimize the chance of it reaching the vitreous.  
We initially demonstrated that topical glucose reached the vitreaous in pseudophakic 
patients. In phakic patients, the crystalline lens may be acting as a physical or 
metabolic barrier. We then showed that topical glucose temporarily improved the 
average contrast sensitivity at 12 cycles/degree. This effect was repeated in a follow–
up study which matched the osmolarity of the saline control to the glucose. 
Although these data indicated that glucose was acting as a “neurorecoverant” at the 




However, we plan to test this hypothesis with a similar study but with retinal 
electrophysiology as the primary endpoint. The study motivates further retinal 
bioenergetics research which could conceivably trial related energy substrates in a 
similar methodological paradigm and more efficient methods of drug delivery in a 
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Legend for Figure 1 
Mean glucose concentration in the vitreous after 50% topical glucose administration 
5–minutely for 60 minutes. *indicates a significant difference compared to the control 





































Legend for Figure 2 
Flow diagram of Study 1 
Assessed for eligibility (n=25 patients; 43 eyes)  
 Excluded  (n = 9 patients; 14 eyes) 
 Not meeting inclusion criteria (n = 5 patients; 9 
eyes) 
 Declined to participate (n = 4 patients; 5 eyes) 
 Other reasons (n= 0)  
) 
 Randomly allocated to treatment or control  
 Received allocated intervention or control (n =16 patients; 29 eyes) 
 Did not receive allocated intervention or control (n = 0) 
Lost to follow–up (give reasons) (n = 0) 
 Total analysed  (n= 16 patients; 29 eyes) 
 Contrast sensitivity analysed (n = 14 patients, 26 eyes) 





Participated (n =16 patients; 29 eyes) 
Crossover 
Enrollment 
 Crossover to receive treatment or control  
 Received allocated intervention or control (n = 16 patients; 29 eyes) 











Legend for Figure 3 
Box plot showing the change in contrast sensitivity at 12 cycles/degree in the 









Legend for Figure 4 
Box plot showing the change in logMAR acuity in the glucose–treated and control 




















Legend for Figure 5 
Glucose significantly increased contrast sensitivity at 12 cycles/degree by 0·26 log 















Legend for Figure 6 




























Legend for Figure 7 
Flow diagram for Study 2 
Assessed for eligibility (n = 8 patients; 16 eyes)  
 Excluded  (n = 1 patients; 2 eyes) 
 Declined to participate (n=1 patients; 2 eyes) 
 Other reasons (n= 0)  
 
 Randomly allocated to treatment or control  
 Received allocated intervention or control (n = 7 patients; 14 eyes) 
 Did not receive allocated intervention or control (n = 0) 
Lost to follow–up (give reasons) (n = 0) 
 Total analysed  (n = 7 patients; 14 eyes) 
 Contrast sensitivity analysed (n = 6 patients, 11 eyes) 





Participated (n=7 patients; 14 eyes) 
Crossover 
Enrollment 
 Crossover to receive treatment or control  
 Received allocated intervention or control (n = 7patients; 29 eyes) 









Legend for Figure 8 
Box plot showing the change in contrast sensitivity at 12 cycles/degree in the 












Legend for Figure 9 
Box plot showing the change in logMAR acuity in the glucose–treated and control 













Legend for Figure 10 
Glucose significantly improved the mean contrast sensitivity at 12 cycles/degree by 

























Legend for Figure 11 
Log contrast sensitivity at baseline and after glucose or saline control drops in Study 
2. 
